Dynamics of inflammatory markers and interleukin 6 levels during olokizumab therapy: Results of a single-center randomized controlled trial
- 30 April 2026
- journal article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (2)
Abstract
The aim – to evaluate the effect of olokizumab (OKZ) on acute-phase reactants, interleukin (IL) 6, and its soluble receptor (sIL-6R) levels in patients with rheumatoid arthritis (RA) and comorbid depression. Material and methods . A total of 125 patients with RA and comorbid depression were included, including 102 (81.6%) women, with a mean age of 48.5±12.6 years. The majority (86.4%) had high RA activity and had failed stable 12-week therapy with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirty-four (27.2%) patients had failed one or more biological agents. At week 0, all patients were randomized using the sequential numbers method in a 2:2:1 ratio to one of three groups: Group 1 received treatment with sDMARDs + OKZ 64 mg subcutaneously once every 4 weeks (n=49); group 2 – sDMARDs + OKZ 64 mg subcutaneously + psychopharmacotherapy (PPT) (n=51); group 3 – sDMARDs + PFT (n=25). The study duration was 24 weeks. Serum IL-6 concentrations were determined using xMAP multiplex technology on a Bio-Plex Array System analyzer (Bio-Rad, USA) and immunochemiluminescence assay (ICL) on a Cobas e411 analyzer (Roche, Switzerland). Results. The use of OKZ was accompanied by a significant decrease in the level of C-reactive protein (CRP) and calprotectin (CP) in the group as a whole; normalization of the CRP level was noted 4 weeks after the start of therapy (pConclusion . Thus, the use of OKZ is accompanied by a decrease in the levels of acute-phase reactants, CP, IL-6, and sIL-6R. CP can be considered a more sensitive marker for assessing inflammation during OKZ therapy compared to CRP.Keywords
This publication has 31 references indexed in Scilit:
- Olokizumab versus Placebo or Adalimumab in Rheumatoid ArthritisNew England Journal of Medicine, 2022
- IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet, 2021
- Translating IL-6 biology into effective treatmentsNature Reviews Rheumatology, 2020
- Targeting Interleukin-6 Signaling in ClinicImmunity, 2019
- Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?BioDrugs, 2018
- Immunopathogenesis of Rheumatoid ArthritisImmunity, 2017
- Rheumatoid arthritisThe Lancet, 2016
- IL-6 as a keystone cytokine in health and diseaseNature Immunology, 2015
- Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28‐Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score‐II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index‐5 (RADAI‐5), Chronic Arthritis Systemic Index (CASI), Patient‐Based Disease Activity Score With ESR (PDAS1) and Patient‐Based Disease Activity Score Without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI‐RA)Arthritis Care & Research, 2011
- Up‐regulation of interleukin (IL)‐6 receptor gene expression in vitro and in vivo in IL‐6 deprived myeloma cellsFEBS Letters, 1992